Source: Annual Congress 2011 - Treating childhood asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Keller, O. Denk, A. Bucholski, M. Knoch (Graefelfing, Germany). Did inappropriate delivery systems hamper therapeutic efficacy of di-sodium-cromo-glycate (DSCG)? Time for a reappraisal. Eur Respir J 2011; 38: Suppl. 55, 4829

Member's Comments

No comment yet.

Related content which might interest you: Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Which therapeutic options when CPAP fails?  Source: ERS Course 2017 - Paediatric noninvasive ventilation Year: 2017 Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling Source: Annual Congress 2009 - New bronchodilators Year: 2009 Reduction of treatment time for nebulized treatments using a new adaptive aerosol delivery mode Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 How to optimise the efficacy of pharmacological treatments? Source: Annual Congress 2011 - New advances in smoking cessation Year: 2011 Does combination therapy lead to better adherence in asthma? Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Development and evaluation of an educational intervention targeted at optimising adherence with measures to prevent asthma in children with a familial allergic disposition (FOCUS-project) Source: Eur Respir J 2002; 20: Suppl. 38, 329s Year: 2002 When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma? Source: Eur Respir J, 58 (3) 2100304; 10.1183/13993003.00304-2021 Year: 2021 Interferon-? liposome: a new system to improve drug delivery in the treatment of lung cancer Source: ERJ Open Res, 7 (3) 00555-2020; 10.1183/23120541.00555-2020 Year: 2021 How effective are oral steroids in asthma action plans? Source: International Congress 2017 – Asthma management Year: 2017 Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy? Source: Eur Respir J 2006; 28: Suppl. 50, 319s Year: 2006 Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003 Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 A new combination therapeutic approach challenging the current dogma of using inhaled corticosteroids as maintenance only to control asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006 Early detection of asthma exacerbations and the use of action points for treatment decisions in self-management plans Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 Update on novel anticoagulants: indications, dosing alternatives and outcomes Source: International Congress 2018 – Pulmonary embolism: what we need to know Year: 2018